Sarepta Therapeutics’ CEO, Douglas Ingram, will retire from this position by the end of 2026 or upon the appointment of a replacement.
Sarepta has commenced a search of internal and external candidates for Ingram’s replacement, according to an SEC filing.
Ingram, Sarpeta’s CEO since 2017, explained the decision last week on an investor call, citing the need to be in California to support two immediate family members recently diagnosed with Myotonic Dystrophy Type 1 (DM1), the most common form of adult muscular dystrophy.
“This decision was a deeply difficult one for me...as we stand at one of the most exciting moments in our entire history,” said Ingram.
Ingram called the news “a fairly shocking and certainly ironic twist of fate” given that Sarepta inked a collaboration with Arrowhead in November 2024 to develop therapies for skeletal muscle diseases, with plans to pursue up to six discovery targets in muscle or central nervous system disorders. The clinical programs, including SRP-1003 program for DM1, use Arrowhead’s proprietary Targeted RNAi Molecule delivery platform.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!